All Oncology News

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

David Rimm, MD, PhD, discusses whether ADCs should be considered similar to targeted therapy, or whether this class of agents is more akin to chemotherapy.

Experts weigh in on combination approaches and how evolving first-line therapy affects second-line sequencing strategies in advanced EGFR-mutant NSCLC.

A group of researchers from the University of Miami sought to understand why many clinical trials in head and neck cancers fail.

Benjamin A. Weinberg, MD, FACP, discusses the specific therapeutic goals and challenges of third-line metastatic colorectal cancer management.

Research showed that an oncolytic virus could prolong survival in patients with glioblastoma.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses 4-year data from the PATHFINDER trial of avapritinib in advanced systemic mastocytosis.

Ibrutinib plus bendamustine and rituximab prolonged PFS in patients with previously untreated mantle cell lymphoma who achieved a CR.

Roswell Park Comprehensive Cancer Center highlighted key presentations from its researchers at TCT 2026.

The FDA has issued REMS safety updates regarding the use of the denosumab biosimilars Enoby and Ospomyv for patients with breast and prostate cancers.

The portable, noninvasive device has been approved for concomitant use with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.

Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.

Patients with mucosal HNSCC deemed unsuitable for curative-intent CRT achieved a 12-month in-field LRC of 80% with high-dose palliative radiation therapy.

Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.

The FDA approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with PD-L1–positive ovarian cancer who could receive pembrolizumab.

A study from Sylvester Cancer Center suggests that blocking p300 may help resensitize cancer cells to chemotherapy.

An sNDA has been filed with the FDA for aminolevulinic acid topical gel plus RhodoLED red light lamps in superficial basal cell carcinoma.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.

The FDA has approved pembrolizumab plus paclitaxel with/without bevacizumab for PD-L1–positive platinum-resistant ovarian cancer.

Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.

Manish A. Shah, MD, and Raji Shameem, MD, discuss potentially paradigm-shifting results from the HERIZON-GEA-01 study.

A Mayo Clinic study demonstrated how treatment sequencing may affect survival in early-stage pancreatic cancer.

Sunandana Chandra, MD, MS, discusses how resectability, anatomy, prior therapy, and patient fitness guide multidisciplinary treatment decisions in CSCC.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.